MktsMarkets

Ultragenyx Pharmaceutical Inc.
NASDAQ: RAREKey statistics
RARE News
Stories mentioning RARE from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 136,000 | 207,571 | 159,933 | 166,496 | 139,000 | 164,647 | 139,494 | 147,026 |
| Cost of Goods Sold | ||||||||
| Gross Profit | ||||||||
| Operating Expenses | ||||||||
| Research & Development | 187,000 | 203,052 | 216,212 | 164,736 | 166,000 | 187,901 | 170,109 | 161,503 |
| Sales General & Admin | 88,000 | 88,734 | 86,620 | 86,646 | 87,000 | 81,885 | 80,351 | 80,604 |
| Total Operating Expenses | ||||||||
| Operating Income (Loss) | (169,000) | (113,222) | (170,890) | (107,888) | (143,000) | (122,305) | (131,987) | (116,361) |
| Interest Income | 6,000 | 6,343 | 5,863 | 5,794 | 7,000 | 10,044 | 10,731 | 7,401 |
| Interest Expense | ||||||||
| Other Expense | (934.00) | (1,043) | 2,140 | 837.00 | (4,643) | 3,077 | (1,829) | |
| Pretax Income | (184,000) | (127,456) | (179,540) | (114,004) | (150,000) | (132,818) | (133,213) | (130,740) |
| Tax Provision | 1,000 | 1,180 | 873.00 | 947.00 | 1,000 | 384.00 | 303.00 | 858.00 |
| Net Income (Loss) | (185,000) | (128,636) | (180,413) | (114,951) | (151,000) | (133,202) | (133,516) | (131,598) |
| Earnings Per Share (Basic) | (1.84) | (1.30) | (1.81) | (1.17) | (1.57) | (1.47) | (1.40) | (1.52) |
| Earnings Per Share (Diluted) | (1.84) | (1.30) | (1.81) | (1.17) | (1.57) | (1.47) | (1.40) | (1.52) |
| Weighted Average Shares Outstanding (Basic) | 100,600 | 98,600 | 99,771 | 98,460 | 96,300 | 90,500 | 95,494 | 86,581 |
| Weighted Average Shares Outstanding (Diluted) | 100,600 | 98,600 | 99,771 | 98,460 | 96,300 | 90,500 | 95,494 | 86,581 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About RARE
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) is a stock listed on the Nasdaq Stock Market under the ticker symbol RARE. It last traded at $16.08 (Nov 13, 2026, 4:00 PM ET), down 1.2% on the day. That gives Ultragenyx Pharmaceutical a market capitalisation of $1.7B.
Over the past 52 weeks RARE has traded between $12.73 and $39.89.
Revenue for the quarter ended Mar 31, 2026 was $136.0M; a net loss of $185.0M. Revenue was down 2.2% from $139.0M in the quarter ended Mar 31, 2025.
| Quarter ended | Revenue | Net income | Margin |
|---|---|---|---|
| Mar 31, 2026 | $136.0M | -$185.0M | -136.0% |
| Dec 31, 2025 | $207.6M | -$128.6M | -62.0% |
| Sep 30, 2025 | $159.9M | -$180.4M | -112.8% |
| Jun 30, 2025 | $166.5M | -$115.0M | -69.0% |
From Ultragenyx Pharmaceutical’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…